Congresses

Workshop : "Inflammation, Irritability and Abdominal Pain:  Mechanisms and Management" : June 15th 2011, Lille, Faculty of Pharmacy of Lille 2, Linus Pauling Amphi (3 rue du Pr. Laguesse, 59 006 Lille)

Co-organisers  Robin Spiller  Qazim Aziz

Chronic abdominal pain is one of the commonest  causes of presentation to a gastroenterologist. Pain due to functional  GI disease (FGID)  is particularly difficult to manage and has been the focus of considerable research and recent advances in understanding.  While the association of pain with inflammation in inflammatory bowel disease is well recognised more recently immune activation has been found to be commonly associated with  FGID. This programme will examine these new insights and see how far they are relevant to the management of both conditions. This programme will examine the basic mechanisms underlying inflammatory pain and discuss implications for their management in both IBD and FGIDs.

Download the programm

Online registration

Download list of hotels

Sponsor :   

                          

             

Workshop, "Lymphatic system and associated adipose tissue in the pathogenesis of inflammatory bowel disease" : December 3th 2010, Lille, DigestScience  Foundation (Parc Eurasanté, 152 rue du Dr Yersin 59120 Loos)

 Inflammatory bowel diseases (IBD) comprise two types of intestinal disorders Crohn’s disease and ulcerative colitis. They affect approximately 3 million Americans and Europeans and its peak onset is in persons 15 to 30 years of age. Currently there is widespread opinion within the gastrointestinal research community that IBD are caused by genetic susceptibility, abnormal intestinal permeability, interactions between the bacterial flora and surface epithelial cells and dysregulation of the host’s immune response.

The lymphatic system plays critical role in tissue fluid homeostasis, immune defense and metabolic maintenance. Early clinical observations and experimental studies suggested lymphangitis as a primary lesion in Crohn’s disease. This concept, once forgotten, is regaining momentum. The relationship between lymphatic system, adipose tissue and inflammation has been the focus of recent exciting research. Understanding how the lymphatic intestinal system could contribute to the pathogenesis of IBD may lead to the development of new therapeutic strategies.

Download the program

Online registration

Download list of hotels

Sponsor :   

 

Workshop: "Neglected microorganisms ofintestinal flora: Role of yeasts and phages in IBD", Henri Warembourg Faculty of medicine (avenue Eugène Avinée, 59120 Loos), June 4th 2010

Meeting organized between the most renowned international experts in the field :

Yeasts areubiquitous in the human body, and although most of them are beneficial, this is not the case for Candidaalbicans, which has adapted to the digestive tract and is a dreadedopportunistic pathogen responsible for nosocomial infections with high morbidityand mortality.  Recent studies havedemonstrated its role in the evolution of inflammatory bowel disease.  While new antifungals have been developed,and although considerable progress has been made in elucidating its structure,its mechanisms of virulence, its interaction with the immune system and  the conditions necessary for its becominginvasive, much remains to be discovered concerning mutual regulation between C.albicans and the digestive tract.

Viruses arethe most numerous  biological entities onthe planet.  Phages, or viruses whichtarget bacteria, play an essential  rolein microbial balance.

While ithas been demonstrated that the digestive mucous membrane of individuals withCrohn's disease contains significantly more bacteriophages than that of healthysubjects, their role in the ecosystem balance and in the development ofinflammatory diseases has not been elucidated. New therapeutic pathways need to be explored.

Download the program

List of hotels

Sponsor :

 

 

Workshop: "Cutting edge of cell therapy in IBD": 2009, November 20^th, Lille  

The first clinical trials on Tr1-based cellular therapy in Crohn's disease just began.

This innovating therapeutic strategy is driven by three reports: firstly, partial effectiveness of  current treatments, secondly, the important frequency of adverse effects of molecular approaches and, thirdly, the ratio benefit/average cost. 

For the first time, this new therapeutic concept should modify the natural history of the disease by treating attacks and by preventing reccurence.  

Download the program

 

Sponsor :         

 

Workshop: "Microbial, environmental and genetic interactions in the origin of Crohn's disease": October 23, 2009, Lille.  

Meeting organized between the most renowned European experts in the field of epidemiology of Inflammatory Bowel Diseases (IBDs) in order to report on the latest advances in this field and to set up an innovating European study , ORIGIN : Observing Relatives, Immunity, Genetics and the mIcrobiome before the onset of CrohN's disease.